Review Article
Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer’s Disease: A Review of Clinical Trials
Table 3
Clinical trials examined assessing the influence of treatment with memantine in moderate-severe AD.
| First author and no. in the list of references | Severity | Mean age years | Mean MMSE at baseline | Duration of the study | | Test |
|
Fox et al. 2012 [17] | MMSE ≤ 19 | Placebo: 84.4 (6.6) Memantine: 84.9 (6.7) | Placebo: 7.3 (6.4) Memantine: 7.3 (6.2) | 12 weeks | 149 | MMSE SIB NPI CMAI CGI-C |
| Förstl et al. 2011 [18] | MMSE ≤ 27 | | | 6 months | 4305 | MMSE IADL |
| Herrmann et al. 2011 [19] | MMSE 0–15 | | | 3 months | 24 | NPI CGI-C |
| Schulz et al. 2011 [20] | MMSE ≤ 20 | Memantine: Placebo: | 16.0 (3.7) | 12 weeks | 93 | CERAD-NP ACDS-ADL-sev CGI-C |
| Rainer et al. 2011 [21] | MMSE < 20 | | | 4 months | 350 | MMSE CGI |
| Wilcock et al. 2008 [22] | MMSE 14–3 | Memantine: 76.9 (8.4) Placebo: 76.7 (7.9) | Memantine: 9.2 (3.3) Placebo: 9.6 (3.1) | 6 months | 593 | MMSE SIB NPI ACDS-ADL-sev CIBIC-plus |
|
|